🔴 Amneal Pharmaceuticals is trading 4.23% down in pre-market with no confirmed company-specific catalyst

Amneal Pharmaceuticals is trading at $20.60, down 4.23% in pre-market; no confirmed company-specific catalyst for the decline was found.

• Amneal Pharmaceuticals is scheduled to report third-quarter results before market open on November 3. An earnings preview cites analyst expectations of about $814 million in revenue and $0.23 adjusted EPS, but does not link the preview to the decline.
• The broader market is higher in the supplied pre-market context, so it does not explain the stock’s drop.